<DOC>
	<DOCNO>NCT01563783</DOCNO>
	<brief_summary>This Post Market study conduct compare direct indirect cost three approach ( GFA , myomectomy , uterine artery embolization ) treatment symptomatic uterine fibroid .</brief_summary>
	<brief_title>Post Market TRUST Study</brief_title>
	<detailed_description>Uterine fibroid common pelvic neoplasms woman ; severely impact quality life lead indication hysterectomy . Hysterectomy definitive treatment myoma ; however , many patient seek alternative uterine-sparing therapy desire conserve fertility . Myomectomy much-reported surgical option woman symptomatic fibroid , recently , abdominal approach approach choice surgeon . Over time , patient request less invasive procedure minimally invasive , laparoscopic option become popular among patient gynecologist . Standard surgical interventional treatment uterine fibroid costly society health care system . New technology GFA may offer low-cost alternative standard treatment symptomatic uterine fibroid woman desire uterine conservation . This study seek evaluate cost difference three available uterine-sparing technique explore qualitative outcome symptom severity , health relate quality life , overall treatment effect .</detailed_description>
	<mesh_term>Leiomyoma</mesh_term>
	<mesh_term>Myofibroma</mesh_term>
	<criteria>Are ≥ 18 year old menstruating Have symptomatic uterine fibroid Have uterine size ≤ 16 gestational week determine pelvic exam Have fibroid less 10 cm diameter Desire uterine conservation Have normal Pap smear within past 36 month define `` untreated cervical malignancy dysplasia . '' Are willing able comply study test , procedure , assessment tool Are capable provide informed consent . Have contraindication laparoscopic surgery and/or general anesthesia . Are expect high risk , know , significant intraabdominal adhesion ( defined adhesion would require extensive dissection mobilize view surface uterus ) Patients require major elective concomitant procedure ( e.g. , hernia repair ) Are pregnant lactate Have take depot GnRh agonist within three month prior screen procedure Have implant intrauterine fallopian tube device contraception remove least 10 day prior treatment Have chronic pelvic pain know due uterine fibroid Have know suspected endometriosis Stage 3 4 , adenomyosis Have active history pelvic inflammatory disease Have history , evidence , gynecologic malignancy premalignancy within past five year Have pelvic radiation Have nonuterine pelvic mass 3 cm Have cervical myoma Have one completely intracavitary submucous fibroid ( Type 0 ) Type 0/1 submucous fibroid well treat via hysteroscopic method In medical judgment investigator participate study Are willing randomized treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Fibroids</keyword>
	<keyword>Myomas</keyword>
	<keyword>leiomyomata</keyword>
	<keyword>menorrhagia</keyword>
	<keyword>Acessa Procedure</keyword>
	<keyword>Radiofrequency Ablation</keyword>
	<keyword>RFA</keyword>
</DOC>